title: Immune hemolysis after fludarabine-based reduced intensity conditioning and allogeneic PBSC transplantation for CML with minor ABO incompatibility.
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Calixto
authors.forename: Fabiana
authors.initials: F
authors.lastname: Ostronoff
authors.forename: Mauricio
authors.initials: M
authors.lastname: Ostronoff
authors.forename: Alexandre
authors.initials: A
authors.lastname: Sucupira
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Florêncio
authors.forename: Ana Patricia Souto
authors.initials: AP
authors.lastname: Maior
authors.forename: Mariana Coutinho
authors.initials: MC
authors.lastname: Domingues
authors.forename: Visalam
authors.initials: V
authors.lastname: Chandrasekaran
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001787:Blood Group Incompatibility / Q000276:immunology*; D005260:Female; D006461:Hemolysis / Q000276:immunology*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000601:surgery*; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous / Q000276:immunology; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine